Search
Now showing items 1-10 of 27
Defining the role of SF3B1K700E mutations in ER+ breast cancer
(Institute of Cancer Research (University Of London), 2021-09-30)
Mutations in SF3B1, a component of the RNA splicing machinery, underpin a number of aggressive cancers. Hotspot mutations in SF3B1 are present in around 3% of breast cancers, are enriched in oestrogen receptor positive ...
A study of the co-evolution of the genome and epigenome in colorectal cancer using multi-omics profiling
(Institute of Cancer Research (University Of London), 2021-11-30)
Late recurrence in ER+ breast cancer - refining risk prediction beyond 5 years
(Institute of Cancer Research (University Of London), 2021-11-30)
ER positive (ER+) breast cancer has the potential to recur many years following diagnosis. Predicting who is most at risk of recurrence and when this may occur is complex. Risk prediction incorporates clinical, pathological ...
The molecular pathology of infant gliomas
(Institute of Cancer Research (University Of London), 2021-04-30)
Infant high grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumours. I have collected 241 cases ...
Investigating the mehcanisms of drug resistance in gastro-intestinal cancers
(Institute of Cancer Research (University Of London), 2020-03-31)
Despite many effective therapies for gastro-intestinal (GI) cancers, both primary and acquired mechanisms of resistance commonly occur. The subclonal complexity of intra-tumoural heterogeneity in these cancers further ...
Applications of intertumoural, intratumoural and intermolecular heterogeneity for personalised medicine in colorectal cancer
(Institute of Cancer Research (University Of London), 2020-03-31)
Colorectal cancer (CRC) is a heterogeneous disease, both at the molecular level and in the context of patients' responses to treatment. Few biomarkers are currently in place that can help to stratify patients in the clinical ...
Defining the mechanisms of multi-target tyrosine kinase inhibitor resistance in soft tissue sarcoma
Soft tissue sarcomas (STS) are a rare, heterogeneous, and challenging group of cancers to treat effectively. The approval of pazopanib, as well as promising clinical trial data for a number of other multi-target tyrosine ...
A translational study in pancreatic neuroendocrine neoplasms
(Institute of Cancer Research (University Of London), 2019-11-30)
Pancreatic neuroendocrine neoplasms (PanNENs) are rare, highly heterogeneous tumours. There have been significant recent advances in our knowledge of genomic events underlying their pathogenesis. However, treatment decisions ...
Amino acid dependence in acute myeloid leukaemia
(Institute of Cancer Research (University Of London), 2022-05-31)
Acute myeloid leukaemia (AML) is a heterogeneous disease which remains curable in only a minority of patients. Outcome is dismal in the subgroup with adverse genetic features. Amino acid (AA) depletion is a therapeutic ...
Clinical and co-clinical genomics of paediatric solid tumours with a special focus in DIPG
(Institute of Cancer Research (University Of London), 2020-07-31)
Cure rates for paediatric solid cancers have not improved in the last decade. Delivering precision medicine to stratify patients based on their molecular profiling is a key goal to support existing and upcoming adaptive ...